Dong-liang Chen

List of Publications by Year
in descending order

27 papers	2,022 citations	361413 20 h-index	477307 29 g-index
30 all docs	30 docs citations	30 times ranked	3417 citing authors

#	Article	IF	Citations
1	Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. Theranostics, 2017, 7, 4836-4849.	10.0	265
2	Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. Journal of Experimental and Clinical Cancer Research, 2016, 35, 142.	8.6	227
3	Long noncoding RNA XIST expedites metastasis and modulates epithelialâ€"mesenchymal transition in colorectal cancer. Cell Death and Disease, 2017, 8, e3011-e3011.	6.3	170
4	Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. Journal of the National Cancer Institute, 2019, 111, 584-596.	6.3	125
5	Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nature Communications, 2020, 11, 1507.	12.8	121
6	Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology, 2014, 60, 598-609.	7.3	117
7	Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Annals of Translational Medicine, 2019, 7, 640-640.	1.7	103
8	Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis, 2013, 34, 803-811.	2.8	96
9	ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis. Cancer Research, 2018, 78, 1972-1985.	0.9	86
10	Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications. Theranostics, 2016, 6, 1160-1175.	10.0	75
11	The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Molecular Cancer, 2020, 19, 154.	19.2	64
12	microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. Oncotarget, 2015, 6, 10868-10879.	1.8	64
13	The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Molecular Cancer, 2021, 20, 166.	19.2	60
14	L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. Journal of Hematology and Oncology, 2013, 6, 43.	17.0	52
15	Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. Cell Death and Disease, 2016, 7, e2432-e2432.	6.3	49
16	Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation. Theranostics, 2018, 8, 1312-1326.	10.0	46
17	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 18404.	3.3	38
18	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. Journal of Translational Medicine, 2020, 18, 475.	4.4	23

#	Article	IF	Citations
19	A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Scientific Reports, 2015, 5, 17717.	3.3	21
20	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. Gene, 2018, 640, 43-50.	2.2	19
21	Effect of Raf kinase inhibitor protein expression on malignant biological behavior and progression of colorectal cancer. Oncology Reports, 2015, 34, 2106-2114.	2.6	18
22	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592198899.	3.2	17
23	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. Journal of Cancer, 2018, 9, 4325-4333.	2.5	16
24	The emerging role of long non-coding RNAs in the drug resistance of colorectal cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 4735-4743.	0.5	4
25	Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World Journal of Gastroenterology, 2014, 20, 264.	3.3	3
26	Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemotherapy and Pharmacology, 2017, 79, 69-79.	2.3	3
27	The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis. Biomolecules, 2021, 11, 1268.	4.0	1